DE60100625T2 - Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina - Google Patents
Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina Download PDFInfo
- Publication number
- DE60100625T2 DE60100625T2 DE60100625T DE60100625T DE60100625T2 DE 60100625 T2 DE60100625 T2 DE 60100625T2 DE 60100625 T DE60100625 T DE 60100625T DE 60100625 T DE60100625 T DE 60100625T DE 60100625 T2 DE60100625 T2 DE 60100625T2
- Authority
- DE
- Germany
- Prior art keywords
- retinal
- rats
- retina
- compounds
- dpat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001525 retina Anatomy 0.000 title claims description 30
- 150000001875 compounds Chemical class 0.000 title claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 13
- 230000000694 effects Effects 0.000 title claims description 11
- 201000010099 disease Diseases 0.000 title description 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 claims description 21
- 230000002207 retinal effect Effects 0.000 claims description 19
- 208000014674 injury Diseases 0.000 claims description 15
- 208000017442 Retinal disease Diseases 0.000 claims description 13
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 12
- 230000001575 pathological effect Effects 0.000 claims description 10
- 230000008733 trauma Effects 0.000 claims description 9
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- IGKYREHZJIHPML-UNTBIKODSA-N 2-[4-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one;hydron;chloride Chemical compound Cl.O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 IGKYREHZJIHPML-UNTBIKODSA-N 0.000 claims description 4
- -1 Buspiron Chemical compound 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001130 urapidil Drugs 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 3
- 230000007397 epiretinal gliosis Effects 0.000 claims description 3
- 238000002647 laser therapy Methods 0.000 claims description 3
- JITOKQVGRJSHHA-UHFFFAOYSA-M monosodium methyl arsenate Chemical compound [Na+].C[As](O)([O-])=O JITOKQVGRJSHHA-UHFFFAOYSA-M 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000004264 retinal detachment Effects 0.000 claims description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- IPRJDKMLMDPMBH-XFULWGLBSA-N (3r)-n-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C2)=C1CN[C@H]2C(=O)NCC1=CC=C(OCO2)C2=C1 IPRJDKMLMDPMBH-XFULWGLBSA-N 0.000 claims description 2
- GGNCUSDIUUCNKE-RSAXXLAASA-N 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(OCCCNC[C@@H]2OC3=CC=CC=C3OC2)=C1 GGNCUSDIUUCNKE-RSAXXLAASA-N 0.000 claims description 2
- LTBKOSQVBVYJKW-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2h-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(F)=CC=C1C(CC1)=CCN1CCCCN1N=CN=C1 LTBKOSQVBVYJKW-UHFFFAOYSA-N 0.000 claims description 2
- 208000002367 Retinal Perforations Diseases 0.000 claims description 2
- QDLVYMYXOLGZOD-ZMBIFBSDSA-N [(2r)-3,4-dihydro-2h-chromen-2-yl]methyl-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]azanium;chloride Chemical compound Cl.C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 QDLVYMYXOLGZOD-ZMBIFBSDSA-N 0.000 claims description 2
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002053 flibanserin Drugs 0.000 claims description 2
- QYFHCFNBYQZGKW-UHFFFAOYSA-N hydron;8-[4-[(5-methoxy-3,4-dihydro-2h-chromen-3-yl)-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione;chloride Chemical compound Cl.C1OC2=CC=CC(OC)=C2CC1N(CCC)CCCCN(C(C1)=O)C(=O)CC21CCCC2 QYFHCFNBYQZGKW-UHFFFAOYSA-N 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- AHCPKWJUALHOPH-UHFFFAOYSA-N lesopitron Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 AHCPKWJUALHOPH-UHFFFAOYSA-N 0.000 claims description 2
- 229950001590 lesopitron Drugs 0.000 claims description 2
- URMTUEWUIGOJBW-UHFFFAOYSA-N piclozotan Chemical compound ClC1=COC2=CC=CC=C2C(=O)N1CCCCN(CC=1)CCC=1C1=CC=CC=N1 URMTUEWUIGOJBW-UHFFFAOYSA-N 0.000 claims description 2
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 claims description 2
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 2
- 229950000505 tandospirone Drugs 0.000 claims description 2
- RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 claims description 2
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims 1
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 claims 1
- 229950003678 flesinoxan Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003727 serotonin 1A antagonist Substances 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 60
- 241000700159 Rattus Species 0.000 description 49
- 239000003981 vehicle Substances 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 16
- 108091008695 photoreceptors Proteins 0.000 description 14
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 11
- 229960002495 buspirone Drugs 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 208000002780 macular degeneration Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000004281 retinal morphology Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012792 core layer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004243 retinal function Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000002295 serotoninergic effect Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- XVBCZSYHUGVSIB-UHFFFAOYSA-N 3-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridin-1-yl]propanenitrile Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC#N)CC=2)=C1 XVBCZSYHUGVSIB-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- HIHZDNKKIUQQSC-UHFFFAOYSA-N 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3,5-trimethylpyrimidine-2,4-dione Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2C)C)CC1 HIHZDNKKIUQQSC-UHFFFAOYSA-N 0.000 description 1
- CPXKXLSFUJLYFN-UHFFFAOYSA-N 8-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C(N(CCC)CCC)CCCC2=C1 CPXKXLSFUJLYFN-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- VLCDUOXHFNUCKK-UHFFFAOYSA-N N,N'-Dimethylthiourea Chemical compound CNC(=S)NC VLCDUOXHFNUCKK-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Chemical class 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Chemical class CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 229940075525 iron chelating agent Drugs 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 239000011709 vitamin E Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19027900P | 2000-03-17 | 2000-03-17 | |
| US190279P | 2000-03-17 | ||
| PCT/US2001/005700 WO2001070222A2 (en) | 2000-03-17 | 2001-02-23 | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60100625D1 DE60100625D1 (de) | 2003-09-25 |
| DE60100625T2 true DE60100625T2 (de) | 2004-02-26 |
Family
ID=22700682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60100625T Expired - Lifetime DE60100625T2 (de) | 2000-03-17 | 2001-02-23 | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP1263434A1 (enExample) |
| JP (5) | JP2003527423A (enExample) |
| KR (3) | KR20030016239A (enExample) |
| CN (2) | CN1198605C (enExample) |
| AR (1) | AR028258A1 (enExample) |
| AT (1) | ATE247507T1 (enExample) |
| AU (5) | AU2001238552A1 (enExample) |
| BR (3) | BR0109193A (enExample) |
| CA (3) | CA2400637A1 (enExample) |
| DE (1) | DE60100625T2 (enExample) |
| DK (1) | DK1263504T3 (enExample) |
| ES (1) | ES2204848T3 (enExample) |
| MX (3) | MXPA02009071A (enExample) |
| PL (1) | PL203709B1 (enExample) |
| PT (1) | PT1263504E (enExample) |
| TW (1) | TWI268777B (enExample) |
| WO (3) | WO2001070223A1 (enExample) |
| ZA (1) | ZA200206350B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763619B2 (en) | 2000-03-17 | 2010-07-27 | Alcon, Inc. | Compounds with 5-HT1A activity useful for treating disorders of the outer retina |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| JP2003527423A (ja) * | 2000-03-17 | 2003-09-16 | アルコン、インコーポレイテッド | 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 |
| TW593302B (en) * | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| WO2004054572A2 (en) | 2002-12-13 | 2004-07-01 | Alcon, Inc. | Novel benzopyran analogs and their use for the treatment of glaucoma |
| JP2004262812A (ja) * | 2003-02-28 | 2004-09-24 | Rohto Pharmaceut Co Ltd | 眼圧低下剤 |
| JP4808612B2 (ja) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
| US7476687B2 (en) | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
| US6989445B2 (en) | 2003-12-15 | 2006-01-24 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8685924B2 (en) | 2004-08-25 | 2014-04-01 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| WO2006062839A1 (en) | 2004-12-08 | 2006-06-15 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| WO2008024846A2 (en) * | 2006-08-25 | 2008-02-28 | Allergan, Inc. | Brimonidine and timolol compositions |
| EP2896624B1 (en) | 2007-03-28 | 2016-07-13 | Atir Holding S.A. | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof |
| EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
| TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
| NZ628266A (en) | 2009-11-09 | 2016-02-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
| AU2014216112B2 (en) | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| US12343337B2 (en) | 2016-09-29 | 2025-07-01 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
| CN113840600B (zh) | 2019-02-27 | 2026-02-13 | 加利福尼亚大学董事会 | 用于治疗脑疾病的n-取代吲哚和其他杂环化合物 |
| KR20240150417A (ko) | 2021-12-15 | 2024-10-15 | 델릭스 테라퓨틱스, 인크. | 페녹시 및 벤질옥시로 치환된 사이코플라스토겐 및 그의 용도 |
| WO2023118544A1 (en) * | 2021-12-23 | 2023-06-29 | Cilcare Dev | 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02262518A (ja) * | 1989-04-03 | 1990-10-25 | Kaken Pharmaceut Co Ltd | 眼圧調整剤 |
| JP2824863B2 (ja) * | 1989-07-12 | 1998-11-18 | エーザイ株式会社 | α▲下１▼―ブロッカー点眼剤 |
| TW270114B (enExample) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| US5521183A (en) * | 1994-08-30 | 1996-05-28 | Allergan | Use of 5-HT ligands as anti-pruritic agents |
| JP3958391B2 (ja) * | 1995-10-25 | 2007-08-15 | 三菱化学株式会社 | 眼疾患用薬剤 |
| US5998467A (en) * | 1995-10-25 | 1999-12-07 | Mitsubishi Chemical Corporation | Medicine for oculopathy |
| WO1998018458A1 (en) * | 1996-10-31 | 1998-05-07 | Alcon Laboratories, Inc. | Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| JP2003527423A (ja) * | 2000-03-17 | 2003-09-16 | アルコン、インコーポレイテッド | 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 |
-
2001
- 2001-02-20 JP JP2001568421A patent/JP2003527423A/ja active Pending
- 2001-02-20 CA CA002400637A patent/CA2400637A1/en not_active Abandoned
- 2001-02-20 KR KR1020027012169A patent/KR20030016239A/ko not_active Withdrawn
- 2001-02-20 MX MXPA02009071A patent/MXPA02009071A/es unknown
- 2001-02-20 WO PCT/US2001/005432 patent/WO2001070223A1/en not_active Ceased
- 2001-02-20 EP EP01911005A patent/EP1263434A1/en not_active Withdrawn
- 2001-02-20 BR BR0109193-0A patent/BR0109193A/pt not_active Application Discontinuation
- 2001-02-20 AU AU2001238552A patent/AU2001238552A1/en not_active Abandoned
- 2001-02-23 ES ES01918208T patent/ES2204848T3/es not_active Expired - Lifetime
- 2001-02-23 WO PCT/US2001/005740 patent/WO2001070230A2/en not_active Ceased
- 2001-02-23 CN CNB018067646A patent/CN1198605C/zh not_active Expired - Fee Related
- 2001-02-23 BR BR0109230-8A patent/BR0109230A/pt not_active Application Discontinuation
- 2001-02-23 KR KR1020027012171A patent/KR20030009390A/ko not_active Withdrawn
- 2001-02-23 PL PL358306A patent/PL203709B1/pl not_active IP Right Cessation
- 2001-02-23 JP JP2001568420A patent/JP4789231B2/ja not_active Expired - Fee Related
- 2001-02-23 BR BR0109211-1A patent/BR0109211A/pt not_active Application Discontinuation
- 2001-02-23 EP EP01914447A patent/EP1267878A2/en not_active Withdrawn
- 2001-02-23 AU AU2001239836A patent/AU2001239836A1/en not_active Abandoned
- 2001-02-23 DE DE60100625T patent/DE60100625T2/de not_active Expired - Lifetime
- 2001-02-23 CA CA2400639A patent/CA2400639C/en not_active Expired - Fee Related
- 2001-02-23 EP EP01918208A patent/EP1263504B1/en not_active Expired - Lifetime
- 2001-02-23 MX MXPA02009072A patent/MXPA02009072A/es active IP Right Grant
- 2001-02-23 PT PT01918208T patent/PT1263504E/pt unknown
- 2001-02-23 AT AT01918208T patent/ATE247507T1/de active
- 2001-02-23 DK DK01918208T patent/DK1263504T3/da active
- 2001-02-23 CN CN01806620A patent/CN1418100A/zh active Pending
- 2001-02-23 AU AU4531001A patent/AU4531001A/xx active Pending
- 2001-02-23 AU AU2001245310A patent/AU2001245310B2/en not_active Ceased
- 2001-02-23 KR KR1020027012170A patent/KR100749191B1/ko not_active Expired - Fee Related
- 2001-02-23 CA CA002399985A patent/CA2399985A1/en not_active Abandoned
- 2001-02-23 MX MXPA02009073A patent/MXPA02009073A/es unknown
- 2001-02-23 WO PCT/US2001/005700 patent/WO2001070222A2/en not_active Ceased
- 2001-02-23 JP JP2001568428A patent/JP2003527427A/ja not_active Withdrawn
- 2001-03-15 AR ARP010101211A patent/AR028258A1/es not_active Application Discontinuation
- 2001-03-16 TW TW090106235A patent/TWI268777B/zh not_active IP Right Cessation
-
2002
- 2002-08-08 ZA ZA200206350A patent/ZA200206350B/en unknown
-
2005
- 2005-06-15 AU AU2005202600A patent/AU2005202600B2/en not_active Ceased
-
2010
- 2010-11-24 JP JP2010261857A patent/JP2011037901A/ja not_active Withdrawn
-
2011
- 2011-05-13 JP JP2011108785A patent/JP2011153158A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763619B2 (en) | 2000-03-17 | 2010-07-27 | Alcon, Inc. | Compounds with 5-HT1A activity useful for treating disorders of the outer retina |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60100625T2 (de) | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina | |
| DE60024407T2 (de) | (2-imidazolin-2-yl-amino)quinoxaline zur behandlung von neuralen verletzungen | |
| AU2001245310A1 (en) | Compounds with 5-HT1A activity useful for treating disorders of the outer retina | |
| US20100168121A1 (en) | Compounds with 5-ht1a activity useful for treating disorders of the outer retina | |
| AT394190B (de) | Phenylcarbamate | |
| DE69636012T3 (de) | Verwendung von (2-imidazolin-2-yl-amino)quinoxalinen zur behandlung von augennervverletzung | |
| DE3780972T2 (de) | Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration. | |
| DE602004005617T2 (de) | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie | |
| DE2901477A1 (de) | Thienohydantoinderivate und diese enthaltende arzneimittel | |
| DE68918099T2 (de) | Pharmazeutische behandlung einer augenentwicklung. | |
| DE69625877T2 (de) | Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms | |
| DE3805744C2 (de) | Phenylcarbamate zur Hemmung der Acetylcholinesterase | |
| DE69114470T2 (de) | Komposition für die behandlung von augenschmerzen. | |
| DE69621633T2 (de) | Verwendung von levo-enantiomeren des medetomidins | |
| JP2002528416A (ja) | 外網膜の疾患の治療 | |
| DE69029734T2 (de) | Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG | |
| DE60006584T2 (de) | Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina | |
| DE69932834T2 (de) | Neue Peptide | |
| DE3779991T2 (de) | Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen. | |
| DE60319021T2 (de) | Verfahren zur Behandlung von Sepsis | |
| HK1051504B (en) | Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina | |
| DE3844992B4 (de) | Hydrogentartrat eines Phenylcarbamats | |
| DE60012163T2 (de) | Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck | |
| MXPA01004175A (en) | Treatment of disorders of the outer retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |